Future blood testing for inclusive monitoring and personalised analytics Network+

英国社区对实验室血液检测的需求非常高，分析表明，远程血液监测在未来将发挥重要作用，使患者和卫生专业人员能够远程进行自己的检测，极大地造福患者并加快决策。COVID-19大流行进一步凸显了远程和联网血液检测的需求，这超出了NHS门诊环境中的在线虚拟诊所。在目前的社区医疗血液检测服务中，在没有培训和实验室设施的情况下，在临床环境之外获得和处理血液样本是具有挑战性的，并且患者需要参加GP手术或医院进行测试，具有旅行负担和感染风险。许多血液分析是分批进行的，需要很长时间才能完成，这意味着常规检测的血液样本分析速度和诊断所需的时间是进一步的挑战。尽管最近在护理点方面进行了创新，但实际上目前的血液分析工具主要是机械或劳动密集型的，需要大量的过滤和手动调整，不适合定期在家监测和纵向分析。没有个性化的实时方法可以随着时间的推移告知疾病的复杂性和病情，这对于早期发现急性疾病和管理慢性疾病至关重要。在英格兰，大约95%的临床路径依赖于患者获得高效，及时和具有成本效益的病理学服务，每年进行5亿次生化和1.3亿次血液学检测。这意味着低效率和不频繁的血液检测会导致诊断延迟，对疾病进展的不完全了解以及广泛人群中的潜在并发症。考虑到这些挑战和当前医疗保健领域的数字化转型，这是一个及时的机会，可以将研究人员，临床医生和实业家聚集在一起，共同应对血液监测和分析的挑战。拟议的Network+将建立一个跨学科的社区，探索未来的血液检测解决方案，以实现远程，包容，快速，负担得起和个性化的血液监测，并应对社区卫生和护理方面的上述挑战。为了实现网络+的愿景，将通过网络+中的信息和通信技术（ICT），数据和分析科学，临床科学，应用光学，生物化学，工程和社会科学之间的合作进行技术研究。该网络将解决血液检测中的三个关键技术挑战：远程监控，ICT，个性化数据和AI，适用于一系列示例临床领域，包括癌症，自身免疫性疾病，镰状细胞病，术前护理，病理学服务和一般初级保健。

There is an extremely high demand for laboratory-based blood tests from community settings in the UK and analysis suggests an important role in the future for remote blood monitoring that would enable patients and health professionals to carry out their own tests remotely, greatly benefiting patients and speeding up decision making. The COVID-19 pandemic has further highlighted the need for remote and connected blood testing that is beyond the online virtual clinics in the NHS outpatient setting. In current blood testing services for community healthcare, it is challenging to obtain and process blood samples outside of the clinical setting without training and lab facilities, and patients are required to attend a GP surgery or hospital for tests with travel burden and infection risk. Many blood analyses are done in batches that take a long time to build up, meaning the speed of blood sample analysis of routine tests and time taken for diagnosis are further challenges. Despite recent innovations in point of care, current blood analysis tools in practice are mainly mechanical or labour-intensive that require extensive filtering and manual tweaking and not suitable for regular at-home monitoring and longitudinal analytics. There is no personalised real-time approach available to inform disease complexity and conditions over time, which are critical for early detection of acute diseases and the management of chronic conditions. In England, around 95% of clinical pathways rely on patients having access to efficient, timely and cost-effective pathology services and there are 500 million biochemistry and 130 million haematology tests are carried out per year. This means inefficient and infrequent blood testing leads to late diagnosis, incomplete knowledge of disease progression and potential complications in a wide range of populations. Taking those challenges into account and current digital transformation in healthcare, this is a timely opportunity to bring researchers, clinicians and industrialist together to address the challenges of blood monitoring and analytics.The proposed Network+ will build an interdisciplinary community that will explore future blood testing solutions to achieve remote, inclusive, rapid, affordable and personalised blood monitoring, and address the above challenges in community health and care. To achieve the Network+ vision, research of technologies will be conducted from collaborations among information and communication technology (ICT), data and analytical science, clinical science, applied optics, biochemistry, engineering and social sciences in the Network+. The network will address three key technical challenges in blood testing: Remote monitoring, ICT, Personalised data and AI in a range of examplar clinical areas including cancer, autoimmune diseases, sickle cell disease, preoperative care, pathology services and general primary care.